AVCO performed well yesterday and ended up closing in the green for a second straight session.

StockWireNews

Complete Tuesday Morning Update On Nasdaq Idea (AVCO)

February 1st

Greetings Readers,

AVCO performed well yesterday and ended up closing in the green for a second straight session.

This could be a big sign for things to come.

After a strong green close to end Friday's session, AVCO continued marching up the charts Monday to a high of $.84.

Though it pulled back slightly from that level, AVCO is up dramatically in a short period of time from this past Thursday's closing valuation of $.681.

Furthermore, AVCO is now trading above several lines of potential support.

Those lines include its:

  • 5-Day Simple Moving Average (SMA)
  • 20-Day SMA
  • 5-Day Exponential Moving Average (EMA)
  • 13-Day EMA

Could this potential support be the building blocks to spark AVCO to continued vertical growth near term?

Get AVCO on your radar this morning and take a moment to read my initial report below if you haven't done so already.

-----

Cancer. What an ugly disease.

At this point, we all have known at least a few people who have been directly impacted by cancer.

Good news is, there are companies out there aiming to battle cancer into submission.

Cellular immunotherapy is an innovative treatment approach that harnesses the body’s own immune system to fight cancer.

The global cellular immunotherapy market is expected to grow from $2.74Bn in 2020 to $3.59Bn in 2021. The market is expected to reach $6.73Bn in 2025.
image

One company I've been keeping track of is appearing to be making major headway in cellular immunotherapy along with several other interesting health related therapies/treatments.

And due to several potential catalysts, it could be on the verge of doing something special.

So for Monday, January 31st, there is only one Nasdaq biotech idea to have on your radar:

*Avalon GloboCare Corp. (AVCO)*
image

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.

And right now, the company has several potential catalysts that could spark a near term vertical chart move. They include:

#1. - End Of Year Business Update, Focus On 2022

#2. - Chairman Provides De-bt Con-version

#3. - Company Advances AI-Enhanced Protein Design Tech

#4. - Filing US & International Patent Application For Breakthrough Tech

So let's break those down quickly...

#1. AVCO Potential Catalyst - End Of Year Business Update, Focus On 2022

Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs

FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update.

[...]

Read the full article here.

-----

#2. AVCO Potential Catalyst - Chairman Provides Debt Conversion

Avalon GloboCare’s Chairman Converts Debt into Common St-ock at 45% Premium to Market

FREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company’s Chairman, Daniel Lu, has converted $3.0Mn of debt owed to him under the Line of Credit into 2.4 million shares of the Company’s common st-ock at $1.25 per share. The conversion price represents a 45% premium to yesterday’s closing price.

[...]

Read the full article here.

-----

#3. AVCO Potential Catalyst - Company Advances AI-Enhanced Protein Design Tech

Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development

FREEHOLD, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced further advancement of the Company’s sponsored research and licensing agreement with the Massachusetts Institute of Technology (MIT). Avalon and MIT have combined their artificial intelligence (AI)-enhanced protein design “QTY Code” technology with Google’s AlphaFold2, a DeepMind AI program developed to predict 3-dimensional (3D) protein structures of previously difficult to work with dr-ug targets. This new system is designed to accelerate and advance Avalon’s capabilities in developing novel targets for immuno-oncology and cellular medicine.

[...]

“This new study with our collaborator, Dr. Shuguang Zhang from MIT, has validated the innovative application of the QTY code technology to transform important cellular therapy targets that have been previously difficult to work with in the laboratory,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This new approach is advancing our capabilities in designing novel immuno-oncology and cellular medicine therapies and we are excited to continue to work with Dr. Zhang to advance these dr-ug development technologies,” added Dr. Jin.

[...]

Read the full article here.

-----

#4. AVCO Potential Catalyst - Filing US & International Patent Application For Breakthrough Tech

Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Dr-ug Delivery and Cellular Immunotherapy

FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation dr-ug delivery and cellular immunotherapy, together with Professor Uwe Sleytr and the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.

[...]

“We are very excited to announce this novel SLET platform, which we believe will help accelerate the development of our mRNA-based Flash-CAR™ program. The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy. In addition, we see a number of other therapeutic and diagnostic applications for this broad and potentially transformative technology platform. Moreover, we believe these latest patent filings will provide us robust international IP protection for this technology and its many potential applications,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.

Read the full article now.

-----

AVCO Recap - 4 Potential Driver Indicators For This Nasdaq Biotech Idea

#1. - End Of Year Business Update, Focus On 2022

#2. - Chairman Provides De-bt Con-version

#3. - Company Advances AI-Enhanced Protein Design Tech

#4. - Filing US & International Patent Application For Breakthrough Tech

-----

Coverage is officially initiated on AVCO. When you have time later, do this:

image

Get AVCO on your radar now.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (AVCO).